iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital Management and Boxer Capital — both existing investors — are leading the financing. iTeos added that its Phase 2 test of belrestotug plus dostarlimab in metastatic PD-L1 high non-small cell lung cancerPD-L1 high non-small cell lung cancer “exceeded pre-defined efficacy criteria” at an interim assessment. Its stock $ITOS was up about 40% on Friday morning. — Jaimy Lee & Ayisha Sharma
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.